UT-SENTRX-ANIMAL-CARE
1.7.2021 16:05:12 CEST | Business Wire | Press release
On May 20th , 2021 Sentrx Animal Care held a ribbon cutting ceremony to celebrate the completion and opening of its brand new 22,000 square foot manufacturing facility in Salt Lake City, Utah. The expansion into this larger new facility represents a major milestone for the Salt Lake City based company. The design of the new space includes 1,689 square feet of ISO 7 clean room and 1,420 square feet of wet lab, accommodating the manufacturing capacity and capabilities required to support Sentrx’s accelerating growth in the United States, and in new markets abroad, as well as expanding R&D initiatives that build upon Sentrx’s patented BioHAnce platform technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005040/en/
Working with Engage Contracting, Inc. as the general contractor on the project, Sentrx broke ground in November 2020. By the end of April 2021, manufacturing was online and fully validated in the new space. Sentrx also completed ISO audits in April and maintains ISO 13485 certification in this new facility.
“The completion of this project marks an exciting milestone for Sentrx,” said Brian Segebrecht, Chief Executive Officer. “Sentrx runs a vertically integrated manufacturing operation, procuring only raw materials and components from third parties. This allows for complete control over quality and the highly proprietary processes we have developed for manufacturing our three in-market formulations at large commercial scale. Our expansion to this new facility ensures our ability to remain a vertically integrated manufacturing operation with the capacity required to support the accelerating growth of our in-market products, as well as the robust pipeline of future innovation we have planned for the BioHAnce platform.”
Sentrx was founded on exclusive, worldwide rights to BioHAnce Technology, a patented and proprietary technology that uses advanced bioengineering to create a molecular matrix of crosslinked hyaluronic acid (HA) that can be specifically modified for each formulation and particular tissue environment, including ocular and skin surfaces. It produces a cellular scaffolding with unique physical and chemical properties that enhances hydration, accelerates the body’s own healing processes, and extends duration in tissue. Sentrx currently sells three product formulations containing the BioHAnce Technology. In the US these products are marketed under the brand names Ocunovis™, Oculenis™ and Episanis™.
Related Information
Sentrx™ Animal Care, Inc. website: www.sentrxanimalcare.com
Online press releases: www.sentrxanimalcare.com/news
Sign up for the Sentrx veterinarian newsletter here
Product information:
Ocunovis™ BioHAnce™ Gel Eye Drops
Oculenis™ BioHAnce™ Ocular Repair Gel
Episanis™ BioHAnce™ Skin and Wound Gel
About Sentrx™ Animal Care, Inc.
Sentrx is a Salt Lake City-based animal health company that develops and manufactures veterinary wound care and ophthalmic products for companion animals. Sentrx transforms complex biotechnologies into easy-to-use care solutions that promote the long-term well-being of animals.
Sentrx was founded on technology from the University of Utah and collaborates with a variety of veterinary academic institutions and practicing veterinarians. The company’s unique combination of medicinal chemistry, bioengineering, and product manufacturing capabilities allow it to deliver cutting-edge animal care solutions. To learn more, visit our website at sentrxanimalcare.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005040/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stonebranch is Again Named a Leader in the 2026 Gartner® Magic Quadrant™ for Service Orchestration and Automation Platforms (SOAPs)10.8.2026 17:00:00 CEST | Press release
Gartner recognizes Stonebranch as a Leader for the third consecutive year based on Completeness of Vision and Ability to Execute. Stonebranch, a leading provider of service orchestration and automation solutions, today announced that it has once again been positioned by Gartner as a Leader in the Magic Quadrant for Service Orchestration and Automation Platforms (SOAPs) for its offering, Universal Automation Center™ (UAC).1 “We’re pleased to be recognized as a Leader for the third year in a row,” said Giuseppe Damiani, CEO at Stonebranch. “To us, this recognition reflects our advancements in helping enterprises orchestrate increasingly complex IT operations with confidence. As organizations modernize their automation strategies and adopt AI, UAC provides the centralized orchestration control plane required to unify traditional automation with AI models and agentic systems. With built-in capabilities like Robi AI, UAC’s agentic copilot, we’re making it easier than ever for teams to build
Frontgrade Expands Huntsville Presence with Advanced R&D Center Supporting Next-Generation Space and Defense Missions10.8.2026 16:09:00 CEST | Press release
New facility in Cummings Research Park brings engineering closer to customers while advancing mission processing technologies and strengthening Frontgrade's long-term investment in Huntsville Frontgrade Technologies ("Frontgrade"), a leading provider of mission-critical electronics and integrated technologies, today announced the opening of its eighth U.S. location in Huntsville, Alabama. Located in Cummings Research Park, the new Advanced Research & Development Center will accelerate the development of next-generation mission processing technologies supporting critical space, defense, intelligence, and national security missions. The Huntsville center expands Frontgrade's engineering capabilities while placing research teams closer to customers, government organizations, industry partners, and leading academic institutions. By working within one of the nation's premier aerospace and defense ecosystems, Frontgrade will accelerate technology development, strengthen customer collaboratio
Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 15:00:00 CEST | Press release
Enterprise AI SaaS leader to accelerate Brightfin's AI-Native platform for IT financial management Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized autho
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 12:00:00 CEST | Press release
Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancersRegional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical
OpenGate Capital to Acquire Maersk Training, the Global Safety Training and Gas-Safety Services Business of Maersk10.8.2026 08:00:00 CEST | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services that operates through two complementary business segments. The first segment, Maersk H2S Safety Services, is a specialist provider of outsourced hydrogen sulphide and Health, Safety and Environment safety services, which include onsite supervision, monitoring and safety equipment maintenance for customers in high-risk operating environments. The second segment, Training Business, is a global provider of safety training, competency development and simulation, delivered through instructor led, digital and virtual
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
